Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 02, 2026 11:51 ET | Source: Research and Markets

Global Tumor Models Market Set to Soar from $2.37B in 2026 to $3.57B by 2030 - 3D Spheroids and Organ-on-a-Chip Propel Tumor Model Advancements

Dublin, April 02, 2026 (GLOBE NEWSWIRE) -- The "Tumor Models Market Report 2026" has been added to ResearchAndMarkets.com's offering. The tumor models market has been experiencing rapid growth,...
March 30, 2026 06:33 ET | Source: Research and Markets

Advanced Melanoma Markets and Companies 2026-2030: Cumulative Revenue to Grow by $1.87 Billion

Dublin, March 30, 2026 (GLOBE NEWSWIRE) -- The "Advanced Melanoma Market Report 2026" has been added to ResearchAndMarkets.com's offering. The advanced melanoma market has demonstrated robust...
March 27, 2026 10:55 ET | Source: Research and Markets

Vulvar Cancer Market Size to Grow by $270 Million During 2026-2030: Investments and Personalized Medicine Drive Market Expansion

Dublin, March 27, 2026 (GLOBE NEWSWIRE) -- The "Vulvar Cancer Market Report 2026" has been added to ResearchAndMarkets.com's offering.The vulvar cancer market has seen significant growth and is...
March 09, 2026 07:00 ET | Source: Castle Biosciences, Inc.

DecisionDx®-Melanoma’s i31-SLNB: Report from the Largest Prospective Multicenter Study to Date Confirms 2.6% Nodal Positivity in Patients Predicted to Have Less Than 5% Risk

Castle announced new data that confirm that the i31-SLNB accurately predicts SLN positivity and identifies low-risk patients who may safely forgo SLNB.
March 06, 2026 07:45 ET | Source: Immuneering Corporation

Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
March 04, 2026 16:30 ET | Source: Castle Biosciences, Inc.

Castle Biosciences to Present Data at SSO 2026 on DecisionDx®-Melanoma’s i31-SLNB, Identifying T1b–T2a Melanoma Patients Who May Safely Avoid SLNB

Castle will share new data evaluating DecisionDx-Melanoma’s i31-SLNB test result for prediction of sentinel lymph node (SLN) positivity at SSO 2026.
February 24, 2026 07:00 ET | Source: Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics Highlights Strong Fourth Quarter and Full Year 2025 Results, Business Achievements and Corporate Updates

~30% Quarterly Revenue Growth Driven by Amtagvi Demand Gross Margin Increased to 50% FY25 Revenue of $264M Achieved Annual Guidance U.S. FDA Fast Track Designation Granted for Lifileucel in...
February 05, 2026 17:15 ET | Source: Iovance Biotherapeutics, Inc.

Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma

SAN CARLOS, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel...
January 21, 2026 11:12 ET | Source: Research and Markets

Photoimmunotherapy Market to Surge with 10.64% CAGR, Reaching USD 3.65 Billion by 2031

Dublin, Jan. 21, 2026 (GLOBE NEWSWIRE) -- The "Photoimmunotherapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031" has been added to ResearchAndMarkets.com's...
January 07, 2026 16:00 ET | Source: Immuneering Corporation

Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP

Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP